What is CJC-1295 / Ipamorelin?
A dual-pathway growth hormone secretagogue combination — combining a synthetic GHRH analogue with a selective ghrelin mimetic to stimulate GH release through two complementary receptor systems.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It incorporates a Drug Affinity Complex (DAC) — a chemical linker that binds to circulating albumin — which extends the peptide's half-life from minutes to approximately one week. This prolonged activity means CJC-1295 can sustain elevated GHRH receptor signalling over extended periods, producing a more consistent pattern of growth hormone release compared to native GHRH.
Ipamorelin is a synthetic pentapeptide (five amino acids) belonging to the growth hormone secretagogue class. It functions as a ghrelin mimetic — a molecule that mimics the action of the endogenous hunger hormone ghrelin by activating the growth hormone secretagogue receptor (GHS-R1a). Together, CJC-1295 and Ipamorelin stimulate growth hormone release through two distinct and complementary pathways: CJC-1295 through the GHRH receptor, and Ipamorelin through the ghrelin receptor. This dual-pathway approach has been the subject of considerable research interest due to the synergistic amplification of GH pulsatility.
Mechanism of Action
Two Receptor Systems, One Hormone
CJC-1295 binds to GHRH receptors (GHRH-R) on somatotroph cells in the anterior pituitary gland. This binding activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP), which triggers the transcription, synthesis, and secretion of growth hormone. The DAC modification ensures sustained receptor activation over days rather than minutes, producing a prolonged elevation in circulating GH levels.
Ipamorelin operates through an entirely separate receptor system. It binds to GHS-R1a — the ghrelin receptor — activating a Gq-protein-coupled signalling cascade. This pathway generates inositol trisphosphate (IP3) and diacylglycerol (DAG), triggering the release of intracellular calcium stores within somatotrophs. The resulting calcium surge drives the exocytosis of stored growth hormone vesicles, producing a discrete, acute GH pulse.
The significance of the dual-pathway approach lies in synergistic amplification. GHRH receptor activation primes the somatotroph cell for GH release, while ghrelin receptor activation triggers the actual secretory event. Research indicates that simultaneous stimulation of both pathways produces a substantially larger GH pulse than activation of either receptor alone — the combined effect exceeds the sum of the individual contributions.
A notable feature of Ipamorelin is its receptor selectivity. Unlike other ghrelin mimetics in the growth hormone secretagogue class — such as GHRP-6 and hexarelin — Ipamorelin does not significantly stimulate the release of cortisol, prolactin, or adrenocorticotropic hormone (ACTH). This selectivity is attributed to Ipamorelin's structure, which appears to activate GHS-R1a in a manner that preferentially engages somatotroph cells over corticotroph and lactotroph cell populations. The practical consequence is a cleaner growth hormone signal with minimal off-target endocrine perturbation.
Body Composition Research
Lean Mass, Fat Mass, and IGF-1
Growth hormone is a primary regulator of body composition. It stimulates lipolysis — the enzymatic breakdown of stored triglycerides in adipocytes into free fatty acids and glycerol — and promotes protein synthesis in skeletal muscle tissue. The pulsatile nature of GH release is itself a research variable: evidence suggests that the amplitude and frequency of GH pulses influence the magnitude and direction of downstream metabolic effects.
CJC-1295/Ipamorelin research has examined effects on lean body mass, fat mass, and circulating insulin-like growth factor 1 (IGF-1) levels. IGF-1, produced primarily by the liver in response to GH stimulation, mediates many of GH's anabolic and metabolic effects. Studies have reported increases in IGF-1 concentrations following CJC-1295/Ipamorelin administration, consistent with enhanced GH-IGF-1 axis activity.
The relationship between GH pulsatility and body composition outcomes is an active area of investigation. Research models suggest that maintaining physiological pulse patterns — rather than sustained, non-pulsatile GH elevation — may produce more favourable shifts in the ratio of lean mass to fat mass. This is one rationale for the combination approach: CJC-1295 provides a sustained baseline elevation of GH-releasing capacity, while Ipamorelin delivers discrete, high-amplitude pulses superimposed on that baseline.
Growth hormone's role in modulating protein and lipid metabolism has been studied extensively in preclinical and clinical research. The capacity to stimulate endogenous GH release through secretagogue administration, while preserving physiological feedback regulation, remains a subject of ongoing investigation in somatotropic pathway research.
Sleep and Recovery
GH Pulsatility and Sleep Architecture
Growth hormone release is not constant throughout the day. The largest and most physiologically significant GH pulse occurs during slow-wave sleep (SWS) — the deep, restorative phase of non-REM sleep that predominates in the first half of the nocturnal sleep period. This sleep-associated GH pulse accounts for the majority of daily GH secretion in healthy adults.
Research into growth hormone secretagogues and sleep architecture has explored how exogenous stimulation of the GH axis interacts with this endogenous circadian pattern. The timing of secretagogue administration relative to sleep onset, and its effects on slow-wave sleep duration, GH pulse amplitude, and total nocturnal GH output, are variables under active investigation.
The relationship between GH and sleep is bidirectional. Not only does sleep drive GH release, but GH itself appears to influence sleep architecture — particularly the amount of time spent in slow-wave sleep. Understanding this feedback loop, and how secretagogue-mediated GH release fits within it, is relevant to research on recovery, tissue repair, and the restorative functions attributed to both sleep and growth hormone.
Ageing is associated with both declining GH secretion (somatopause) and degraded sleep architecture — reduced slow-wave sleep, increased sleep fragmentation, and altered circadian rhythmicity. Whether these two age-related changes are causally linked, and whether restoring GH pulsatility through secretagogue administration can partially reverse sleep deterioration, remains an open question in ageing research.
All products are research compounds intended for laboratory research use only. Not for human or veterinary use. Kinetic Labs does not provide dosing guidance, therapeutic recommendations, or medical advice of any kind.